Intellia Therapeutics NASDAQ: NTLA
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system
Name | Intellia Therapeutics |
Ticker | NTLA |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Gene Editing - Cell Therapies |
Price
52W Low/High |
51.81
9.44 / 83.68 |
Momentum | Weak Down |
Market cap | 3.1 B |
1Y Total Return |
256.82%
Strong |
1Y Volatility |
91.39%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system
Details
Ticker | NTLA |
Name | Intellia Therapeutics |
ISIN | US45826J1051 |
CUSIP | 45826J105 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Gene Editing - Cell Therapies |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 3/5/21
Close Price | 51.81 |
52W Low/High | 9.44 / 83.68 |
Market cap | 3.1 B |
1Y Total Return |
256.82%
Strong |
1Y Volatility |
91.39%
High Risk |
Beta | 3.52 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -231.5% |
Cash from Op. / Cur. Liabilities | -0.78 |
Diluted Earnings / Share | -2.40 |
ROE | - |
ROIC | -38.7% |
Price / Revenue | 50.0 |
Price / Book | 5.5 |
Price / CF | -58.1 |
Current Ratio | 9.6 |
Cur.Liabilities / Tot.Liabilities | 0.4 |
Financial Leverage | 0.07 |
in Mils USD |
rolling-year up to December
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
58
|
43
|
30
|
26
|
16
|
6
|
|
Gross Profit |
58
|
43
|
30
|
26
|
16
|
6
|
|
R&D |
150
|
108
|
89
|
68
|
32
|
11
|
|
EBITDA |
-128
|
-94
|
-81
|
-65
|
-31
|
-13
|
|
Operating Income |
-137
|
-106
|
-91
|
-70
|
-32
|
-13
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
56
|
47
|
43
|
36
|
22
|
0
|
|
EPS exc. Extra |
-2.40
|
-2.11
|
-1.98
|
-1.88
|
-1.42
|
-51.02
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
676
|
334
|
347
|
376
|
299
|
82
|
|
Cash, Eq & Invt ShortTerm |
597
|
280
|
314
|
341
|
273
|
76
|
|
Total Current Assets |
617
|
289
|
325
|
355
|
281
|
78
|
|
Total Non-Current Assets |
60
|
45
|
22
|
21
|
18
|
5
|
|
Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Liabilities |
149
|
64
|
69
|
76
|
89
|
103
|
|
Total Current Liabilities |
64
|
36
|
41
|
31
|
31
|
11
|
|
Long Term Debt |
85
|
29
|
29
|
44
|
58
|
93
|
|
Shareholder equity |
527
|
270
|
278
|
301
|
210
|
-21
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-50
|
-103
|
-61
|
-65
|
36
|
-2
|
|
Depreciation |
6
|
6
|
4
|
3
|
1
|
0
|
|
Cash from Investing |
-214
|
25
|
-261
|
-10
|
-6
|
-3
|
|
Capex |
4
|
7
|
6
|
10
|
6
|
3
|
|
Cash from Financing |
372
|
76
|
40
|
143
|
167
|
70
|
|
Stock Issued |
370
|
75
|
39
|
142
|
168
|
-1
|
|
Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
Free Cash Flow |
-318
|
-73
|
-331
|
-80
|
-24
|
1
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
9.6
|
8.1
|
8.0
|
11.3
|
9.2
|
7.3
|
|
Financial Leverage D/E |
0.07
|
0.07
|
0.00
|
0.00
|
0.00
|
-
|
|
Return on Capital Avg |
-38.7%
|
-40.7%
|
-67.7%
|
-
|
-
|
-
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available